null
SMILES: CC(C)(NC(=O)[C@@H]1[C@H]2CNC[C@@H]12)c1nc2ccc(Cl)cc2[nH]1
InChI Key:
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Somatostatin receptor type 4 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 106 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US10675268 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 4 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 106 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2... | US Patent US10166214 (2019) BindingDB Entry DOI: 10.7270/Q2D50Q16 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 4 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 106 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US9789082 (2017) BindingDB Entry DOI: 10.7270/Q2CN760Q | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 3 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >8.58E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US10675268 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 3 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >8.58E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US9789082 (2017) BindingDB Entry DOI: 10.7270/Q2CN760Q | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 3 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >8.58E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2... | US Patent US10166214 (2019) BindingDB Entry DOI: 10.7270/Q2D50Q16 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 1 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >8.91E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US10675268 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 1 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >8.91E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US9789082 (2017) BindingDB Entry DOI: 10.7270/Q2CN760Q | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 1 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >8.91E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2... | US Patent US10166214 (2019) BindingDB Entry DOI: 10.7270/Q2D50Q16 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 2 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >9.59E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US9789082 (2017) BindingDB Entry DOI: 10.7270/Q2CN760Q | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 2 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >9.59E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US10675268 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 2 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >9.59E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2... | US Patent US10166214 (2019) BindingDB Entry DOI: 10.7270/Q2D50Q16 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 5 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >9.85E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2... | US Patent US10166214 (2019) BindingDB Entry DOI: 10.7270/Q2D50Q16 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 5 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >9.85E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US10675268 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 5 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >9.85E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t... | US Patent US9789082 (2017) BindingDB Entry DOI: 10.7270/Q2CN760Q | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 4 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 8.10 | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia... | US Patent US10166214 (2019) BindingDB Entry DOI: 10.7270/Q2D50Q16 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Somatostatin receptor type 4 (Homo sapiens (Human)) | BDBM311875 (US10166214, Example 11 | US10675268, Example 11 | ...) | KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 8.10 | n/a | n/a | n/a | n/a |
Centrexion Therapeutics Corporation US Patent | Assay Description The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia... | US Patent US10675268 (2020) | |||||||||||
More data for this Ligand-Target Pair |